肌层浸润性膀胱癌:扩散加权MR成像预测新辅助化疗反应
前瞻性纳入58例临床T2-4aN0M0肌层浸润性膀胱癌患者,NAC前后行MRI,以术后病理T分期定义反应者(pTa/pTis/pT1)与非反应者(≥pT2)。反应者治疗前ADC值[1.33(±0.21)]×10-3mm2/s显著高于非反应者[1.09(±0.08)]×10-3mm2/s(P<.001),治疗前ADC值预测NAC反应的AUC最高为0.88(95%CI 0.77,0.95;P<.001)。
要点
- 治疗前ADC值预测NAC反应AUC达0.88,反应者ADC值显著高于非反应者。
- ADC直方图多数参数(Mean及10th-90th百分位)反应者显著高于非反应者(P<.001)。
- 以术后病理T分期为参考标准,pTa/pTis/pT1为反应者,≥pT2为非反应者。
核心结论
- 扩散加权MR成像的ADC值及ADC直方图分析有助于预测肌层浸润性膀胱癌患者的新辅助化疗反应。
研究设计与样本
- 前瞻性研究,纳入58例连续临床T2-4aN0M0肌层浸润性膀胱癌患者,NAC前后行MRI。
- 以术后病理T分期为参考标准:非肌层浸润性残留癌(pTa、pTis、pT1)定义为反应者,肌层浸润性残留癌(≥pT2)定义为非反应者。
- ADC值测量采用单层面感兴趣区,ADC直方图参数来自全肿瘤体积感兴趣区。
- 采用Mann-Whitney U检验或独立样本t检验比较反应者与非反应者,ROC曲线分析评估诊断效能。
诊断标准与关键数值
- 反应者治疗前ADC值[1.33(±0.21)]×10-3mm2/s显著高于非反应者[1.09(±0.08)]×10-3mm2/s(P<.001)。
- 反应者治疗前ADC直方图多数参数(Mean、10th、25th、50th、75th、90th百分位)显著高于非反应者(P<.001)。
- 治疗前ADC值预测NAC反应的AUC最高,为0.88(95%CI 0.77,0.95;P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the usefulness of diffusion-weighted MR imaging with ADC value and histogram analysis of ADC in the prediction of response to neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC).
METHODS: Fifty-eight consecutive patients with clinical T2-4aN0M0 MIBC who underwent MRI before and after NAC were enrolled in the prospective study. The evaluation of response to NAC was based on the pathologic T (pT) stage after surgery. Patients with non-muscle-invasive residual cancer (pTa, pTis, pT1) were defined as responders, while those with muscle-invasive residual cancer (≥ pT2) were defined as non-responders. The ADC value measured from a single-section region of interest and ADC histogram parameters derived from whole-tumor volume of interest in responder and non-responder were compared using the Mann-Whitney U test or independent samples t test. ROC curve analysis was used to evaluate the diagnostic performance of ADC value and ADC histogram parameters in predicting the response to NAC.
RESULTS: The pretreatment ADC value of responders ([1.33 (± 0.21)] × 10-3mm2/s) was significantly higher than that of non-responders ([1.09 (± 0.08)] × 10-3mm2/s) (P < .001). Most of the pretreatment ADC histogram parameters (Mean, 10th, 25th, 50th, 75th, and 90th percentiles) of responders were significantly higher than that of non-responders (P < .001). The AUC was highest for the pretreatment ADC value (0.88; 95% confidence interval: 0.77, 0.95; P < .001).
CONCLUSION: Diffusion-weighted MR imaging with ADC value and histogram analysis of ADC are useful to predict NAC response in patients with MIBC.
引用
- Zhang, Wang, Zhang, et al. Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging. Abdom Radiol (NY). 2022. PMID: 35306580. doi:10.1007/s00261-022-03455-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。